BY ANJA HAUGE
-
Professor on Novo Nordisk’s historic savings plan: Four challenges require top management’s focus
Novo Nordisk need to guarantee that the pipe does not come to be also limited which the business’s credibility does not endure long-term damages as a result of team cuts, cla…
-
Professor on Novo Nordisk’s historic savings plan: Four challenges require top management’s focus
Novo Nordisk must ensure that the pipeline does not become too tight and that the company’s reputation does not suffer lasting damage due to staff cuts, says professor.
-
ALK’s allergic shock nasal spray distribution lags: “We must break some habits”
2 certain obstacles have actually gone to play throughout the quarter when it involves ALK’s Neffy nose spray, claims chief executive officer.
-
Analyst: Lundbeck may withdraw from Irish takeover battle
Sydbank expert states Lundbeck might be restricted after in 2015’s purchase of Longboard. Consequently, it is not particular that the firm will certainly make a brand-new quo…
-
After rejected takeover: Bavarian Nordic now pursuing acquisitions without private equity backing
The Danish injection business should expand much faster, states CFO Henrik Juuel in a meeting with MedWatch, additionally mentioning what Bavarian Nordic is trying to find in a bra…
-
Lundbeck overtaken as Alkermes raises bid for Irish acquisition target
The enhanced deal currently values Avadel at as much as USD 2.37 bn, according to a declaration from the business.
-
Analyst: Lundbeck may withdraw from Irish takeover battle
Sydbank analyst says Lundbeck may be limited after last year’s acquisition of Longboard. Therefore, it is not certain that the company will make a new bid for Irish company Avadel.
-
ALK’s allergic shock nasal spray distribution lags: “We must break some habits”
Two particular challenges have been at play during the quarter when it comes to ALK’s Neffy nasal spray, says CEO.
-
ALK invests heavily in children’s allergies after strong quarter
The allergic reaction business will certainly keep energy for the remainder of the year by buying locations such as electronic modern technology and market accessibility.
-
Inside the numbers: Production bears the brunt of Novo Nordisk’s historic mass layoffs
Novo Nordisk has spent DKK 9.455bn on its cost-cutting plan. MedWatch provides a breakdown of expenses.
